ONC NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

BeiGene, Ltd. · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 325.9 USD
4.4% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is 5.7% above the Trend Line and sits at 54.8% of its 52-week range. The latest completed week returned 4.4%, after a 16.4% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is mixed with 41/100 conviction, while the latest news-sentiment score is 58/100. Near-term considerations: earnings are due in 7d.

Setup score 55 out of 100
Latest Close 325.9 USD 24 Jul 2026
1W Return 4.4% latest completed week
4W Return 16.4% short-term follow-through
12W Return 10.9% quarterly tape
Trend Breadth 59.6% 31 of 52 weeks active
Volume Ratio 1.6x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.4% Latest completed week; four-week move 16.4%. Indicator stack 33/81 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 41/100 conviction; expected move 15.3%. News sentiment 58/100 17 relevant articles in the latest sentiment read. Event risk 7d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 5.7% above the Trend Line and sits at 54.8% of its 52-week range. The latest completed week returned 4.4%, after a 16.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1612-week average 0.11

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.16Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 16.4% over four weeks, 10.9% over 12 weeks, and 11.8% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.4%
4W16.4%
12W10.9%
26W-4.0%
52W11.8%
Active trend streak0 weeks
Active weeks in one year31
Trend breadth59.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.69Latest activity-pressure read.
Pressure change234.5%Four-week change in activity pressure.
Leadership-5.49Latest relative-leadership reading.
RS change75.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength19/100Blend of value, momentum, and quality. Underlying universe rank 82; rank 1 is best.
Value5/100Relative valuation strength. Underlying universe rank 96; rank 1 is best.
Quality99/100Profitability and accounting quality. Underlying universe rank 2; rank 1 is best.
Momentum31/100Medium-term price momentum. Underlying universe rank 70; rank 1 is best.
Growth85/100Revenue and earnings growth. Underlying universe rank 16; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework25/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
65.9x
Price divided by trailing earnings.
Price / sales
5.9x
Market value relative to trailing revenue.
EV / EBITDA
33.5x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
5.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
88.3%
Gross profit retained from each unit of revenue.
Operating margin
13.1%
Operating profit retained from revenue.
Free-cash-flow margin
30.0%
Free cash flow generated from revenue.
Return on invested capital
52.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
37.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
159.5%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.5%
Net share repurchases relative to market value.
Shareholder yield
-0.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-4.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

ONC shows mixed options pressure with a 41/100 conviction score, put-call volume ratio of 1.35, expected move of 15.3%, and Sharemaestro trend signal inactive.

Conviction41/100
Expected move15.3%
Put/call volume1.35
Pressure-10
Speculation43
Volatility81
Trend agreement72
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment58/100

Weighted news tone is neutral across 17 relevant articles.

7 positive · 7 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings7dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move15.3%Nearest-chain priced movement where available.
52-week drawdown-15.4%Distance below the 52-week high.
13-week volatility4.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+9.8%Week of 3 Apr.
Worst week-12.5%Week of 27 Feb.
Latest week+4.4%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains6
Flat weeks0
Modest losses5
Sharp losses7
Recent vol4.8%13-week weekly-return volatility.
Base vol5.4%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew5.0% / -3.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape48/100

Trend, activity pressure, participation, and risk combine to a 48/100 tape read.

 Indicator analysis15/100

Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.

Activity pressure 0.16; No reversal markers Factors38/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 75 SVQF25/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 542.0 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options54/100

ONC shows mixed options pressure with a 41/100 conviction score, put-call volume ratio of 1.35, expected move of 15.3%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 15.3% Sentiment58/100

Weighted news tone is neutral across 17 relevant articles.

BeiGene(ONC.US) Officer Sells US$34.59 Million in Common Stock Insiders50/100

No recent insider transaction evidence is stored.

 Earnings7d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 2026325.9 USD4.4%308.4 USD235.8 USD0.69-5.492.3MOff
17 Jul 2026312.0 USD4.5%307.9 USD235.2 USD0.29-11.102.6MOff
10 Jul 2026298.7 USD0.4%308.0 USD234.4 USD-0.10-18.681.4MOff
3 Jul 2026297.6 USD6.3%308.7 USD233.8 USD-0.27-17.621.3MOff
26 Jun 2026279.9 USD3.6%309.6 USD233.1 USD-0.52-21.951.3MOff
19 Jun 2026270.1 USD2.1%311.6 USD232.4 USD-0.72-28.181.4MOff
12 Jun 2026264.5 USD-2.1%314.2 USD231.9 USD-0.67-28.091.9MOff
5 Jun 2026270.1 USD-6.2%317.6 USD231.5 USD-0.72-25.281.3MOff
29 May 2026287.9 USD-7.2%319.2 USD231.1 USD-0.59-24.23854.7KOff
22 May 2026310.2 USD5.8%320.0 USD230.7 USD-0.62-16.261.2MOff
15 May 2026293.3 USD-6.0%320.0 USD230.2 USD-0.81-20.011.3MOff
8 May 2026312.1 USD6.2%320.8 USD229.9 USD-0.75-15.221.3MOff
1 May 2026293.9 USD-2.3%321.0 USD229.4 USD-0.87-15.91791.9KOff
24 Apr 2026300.8 USD-7.1%322.7 USD229.1 USD-0.78-12.881.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.